On April 29, 2021 Hexagon reported that Interim Report 1 January – 31 March 2021 (Press release, Hexagon Bio, APR 29, 2021, View Source;31-march-2021-301280107.html [SID1234578853]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

First quarter 2021

Net sales increased by 10 per cent to 977.9 MEUR (889.9). Using fixed exchange rates and a comparable group structure (organic growth), net sales increased by 11 per cent
Adjusted operating earnings (EBIT1) increased by 34 per cent to 257.9 MEUR (192.4)
Earnings before taxes, excluding adjustments, amounted to 250.3 MEUR (186.6)
Net earnings, excluding adjustments, amounted to 205.2 MEUR (153.0)
Earnings per share, excluding adjustments, amounted to 0.56 EUR (0.41)
Operating cash flow increased to 211.9 MEUR (136.9)
For further information please contact:

Maria Luthström, Head of Sustainability and Investor Relations, Hexagon AB, +46 8 601 26 27, [email protected]

This information is information that Hexagon AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 13:00 CET on 29 April 2021.

This information was brought to you by Cision View Source

View Source;31-march-2021,c3336589